Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BDSX
Upturn stock ratingUpturn stock rating

Biodesix Inc (BDSX)

Upturn stock ratingUpturn stock rating
$0.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: BDSX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $1.8

1 Year Target Price $1.8

Analysts Price Target For last 52 week
$1.8Target price
Low$0.17
Current$0.28
high$2.04

Analysis of Past Performance

Type Stock
Historic Profit -53.27%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 36.68M USD
Price to earnings Ratio -
1Y Target Price 1.8
Price to earnings Ratio -
1Y Target Price 1.8
Volume (30-day avg) 6
Beta 0.98
52 Weeks Range 0.17 - 2.04
Updated Date 06/30/2025
52 Weeks Range 0.17 - 2.04
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.27

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -54.28%
Operating Margin (TTM) -50.47%

Management Effectiveness

Return on Assets (TTM) -23.33%
Return on Equity (TTM) -1454.41%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 81557258
Price to Sales(TTM) 0.49
Enterprise Value 81557258
Price to Sales(TTM) 0.49
Enterprise Value to Revenue 1.1
Enterprise Value to EBITDA -2.72
Shares Outstanding 146563008
Shares Floating 62032803
Shares Outstanding 146563008
Shares Floating 62032803
Percent Insiders 52.11
Percent Institutions 36.46

Analyst Ratings

Rating 3
Target Price 1.8
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Biodesix Inc

stock logo

Company Overview

overview logo History and Background

Biodesix, Inc. was founded in 2005 and is headquartered in Boulder, Colorado. It focuses on developing and commercializing diagnostic tests for lung cancer and other pulmonary diseases.

business area logo Core Business Areas

  • Lung Diagnostic Tests: Develops and sells blood-based diagnostic tests to improve treatment decisions and outcomes for lung cancer patients. Offerings include Nodify Lung, GeneStrat, and VeriStrat.
  • Pulmonary Disease Testing: Offers tests for other pulmonary diseases beyond lung cancer, aimed at improving diagnosis and management.
  • Biomarker Discovery: Conducts research and development activities to discover and validate new biomarkers for disease detection.

leadership logo Leadership and Structure

The leadership team includes Scott Hutton (CEO). The organizational structure consists of research, development, commercial, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • Nodify Lung Nodule Risk Assessment: A blood-based test to assess the risk of malignancy in lung nodules. Competitors: Veracyte (VCYT) with Percepta Nasal Swab, and other imaging techniques. Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.
  • GeneStrat DDx Alteration Identification: A blood-based test for genomic profiling of advanced lung cancer. Competitors: Guardant Health (GH), Foundation Medicine (owned by Roche). Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.
  • VeriStrat Proteomic Profiling: A blood-based test used to stratify patients and predict response to EGFR inhibitors and other treatments for lung cancer. Competitors: Thermo Fisher Scientific (TMO) with Oncomine assays, and other proteomic profiling methods. Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.

Market Dynamics

industry overview logo Industry Overview

The diagnostic testing market is growing, driven by increasing cancer incidence and technological advancements. The lung cancer diagnostics segment is highly competitive, with many companies developing and commercializing new tests.

Positioning

Biodesix is positioned as a provider of non-invasive blood-based diagnostic tests for lung cancer. Its competitive advantage lies in its proprietary technologies and expertise in biomarker discovery.

Total Addressable Market (TAM)

The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a significant share of this market through its innovative product offerings.

Upturn SWOT Analysis

Strengths

  • Proprietary technologies
  • Expertise in biomarker discovery
  • Blood-based diagnostic tests offer a non-invasive approach
  • Established commercial infrastructure

Weaknesses

  • Limited market share compared to larger competitors
  • Reliance on a few key products
  • Cash burn rate is concerning

Opportunities

  • Expanding product portfolio to include other pulmonary diseases
  • Partnering with pharmaceutical companies to develop companion diagnostics
  • Increasing adoption of blood-based diagnostics in clinical practice
  • Geographic expansion

Threats

  • Competition from larger diagnostic companies
  • Regulatory changes
  • Reimbursement challenges
  • Technological advancements may render existing tests obsolete

Competitors and Market Share

competitor logo Key Competitors

  • VCYT
  • GH
  • TMO

Competitive Landscape

Biodesix faces competition from larger diagnostic companies with more resources. Its advantage lies in its specialized focus on lung cancer diagnostics.

Growth Trajectory and Initiatives

Historical Growth: Biodesix's growth has been driven by the adoption of its lung cancer diagnostic tests. Growth rates should be checked against financial reports.

Future Projections: Future growth projections depend on market adoption of new products and expansion into new markets. - Data would require a live source.

Recent Initiatives: Recent initiatives may include new product launches, partnerships, and acquisitions. - Data would require a live source.

Summary

Biodesix is a focused lung cancer diagnostics company with proprietary technologies. It faces strong competition from larger players, but has opportunities for growth through product expansion and partnerships. Its financial performance and cash burn require monitoring. Successful execution of its growth strategy is critical for long-term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is based on available information and is not financial advice. Market share data are estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biodesix Inc

Exchange NASDAQ
Headquaters Louisville, CO, United States
IPO Launch date 2020-10-28
President, CEO & Director Mr. Scott Hutton
Sector Healthcare
Industry Diagnostics & Research
Full time employees 273
Full time employees 273

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.